Ratio Improvement: Despite absolute muscle loss, the STEP 1 trial showed that the proportion of lean mass relative to total body weight actually increased
1 syringe per injection
Studies have found that those using Semaglutide GLP-1 lost up to 10% of their body weight over a period of 16 weeks, compared to those not using Semaglutide GLP-1, who lost an average of 3%
While formal evidence remains in development, the mechanistic rationale is compelling: sustained, gentle GLP-1 receptor activation may favorably influence glucose metabolism, cardiovascular integrity, and neuroprotection, all while maintaining tolerability and adherence
Hormonal effects related to IGF-1 and androgen sensitivity may play a role
Your prescription is filled through a licensed compounding pharmacy and dispensed with handling guidance, storage instructions, and an assigned beyond-use date